ABT-263

Name: ABT-263
SKU: A0777
Availability: InStock

Product ID A0777

Cas No. 923564-51-6

Purity ≥99%

Product Unit Size	Cost	Quantity		Stock

Bulk Quote

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description

ABT-263 is a BH3 mimetic that inhibits Bcl-2, Bcl-ω, and Bcl-xl. ABT-263’s inhibition of Bcl-xl results in thrombocytopenia by inducing apoptotic death of platelets, limiting its usage. ABT-263 exhibits anticancer chemotherapeutic activity and shows some benefit in clinical trials. In chronic lymphocytic leukemia (CLL) cells, ABT-263 inhibits cell proliferation. In cellular and animal models of cancers with solid tumors, ABT-263 enhances the chemotherapeutic activity of several co-administered treatments.

Product Info

Cas No.	923564-51-6
Purity	≥99%
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
Formula Wt.	974.61
IUPAC Name	4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide
Synonym	Navitoclax, A-855071
Solubility	DMSO 100 mg/mL (102.6 mM) Water Insoluble Ethanol Insoluble
Appearance	White to off white powder

Shipping and Storage

Store Temp	4°C
Ship Temp	Ambient

Downloads

MSDS	A0777 MSDS PDF
Info Sheet	A0777 Info Sheet PDF

References

Debrincat MA, Pleines I, Lebois M, et al. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis. 2015 Apr 16;6:e1721. PMID: 25880088.

Khaw SL, Mérino D, Anderson MA, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014 Jan 9. [Epub ahead of print]. PMID: 24402163.

Balakrishnan K, Gandhi V. Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs. 2013 Oct;31(5):1384-94. PMID: 23907405.

Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012 Jun 1;18(11):3163-9. PMID: 22496272.

Chen J, Jin S, Abraham V, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10(12):2340-9. PMID: 21914853.

Custom Order

Name*
First Last
Company/Institution
Email*
Enter Email Confirm Email
Product ID
Product Name
Unit Size
Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
Unit Label
Quantity
Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
Comments
Comments
This field is for validation purposes and should be left unchanged.

ABT-263

Quicklinks

Description

Product Info

Shipping and Storage

Downloads

References

Custom Order

Related Products

7-(Triethylsilyl)-baccatin III

Alternariol

Fenofibrate

18β-Glycyrrhetinic Acid

Ricobendazole

Papain Inhibitor

Paclitaxel, 8-Hydro-bicyclo(3.3.0)octane

10-Deacetyltaxol B

Schisantherin A

Neuromedin

Growth Hormone Releasing Hexapeptide

Pimecrolimus

Bromhexine Hydrochloride

Dantrolene Sodium Heptahydrate

Amifostine Trihydrate

Ceftriaxone Disodium Hemiheptahydrate

Anacetrapib

Diacerein

10,13-Bissidechain Paclitaxel

Luteinizing Hormone Releasing Hormone III, lamprey

Footer